Literature DB >> 19685202

Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep.

Maria Giuseppina Baglietto1, Maria Margherita Mancardi, Alessandro Giannattasio, Nicola Minuto, Andrea Rossi, Giuseppe Capovilla, Edvige Veneselli, Renata Lorini, Giuseppe d'Annunzio.   

Abstract

Hyperglycemic status may be rarely complicated by Epilepsia partialis continua (EPC) that usually responds to metabolic normalization. Anti-glutamic acid decarboxylase antibodies (GAD-Ab) play a pivotal role in the autoimmune process that leads to clinical onset of type 1 diabetes mellitus (T1DM). GAD-Ab have been recently reported in association with rare forms of refractory epilepsy, with or without association to T1DM. Here we describe a young patient who developed EPC five months after T1DM onset; GAD-Ab were detected in his cerebrospinal fluid with evidence of oligoclonal bands. His epileptic disorder evolved over time into drug-resistant epilepsy with continuous spike-waves during slow sleep and severe behavioral impairment. The role of both metabolic imbalance and GAD autoimmunity is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19685202     DOI: 10.1007/s10072-009-0122-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  13 in total

1.  Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

Authors:  S Vulliemoz; G Vanini; A Truffert; C Chizzolini; M Seeck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

2.  Steroids in intractable childhood epilepsy: clinical experience and review of the literature.

Authors:  Helene Verhelst; Paul Boon; Gunnar Buyse; Berten Ceulemans; Marc D'Hooghe; Linda De Meirleir; Danièle Hasaerts; An Jansen; Lieven Lagae; Alfred Meurs; Rudy Van Coster; Kristl Vonck
Journal:  Seizure       Date:  2005-09       Impact factor: 3.184

Review 3.  The pathogenesis of insulin-dependent diabetes mellitus.

Authors:  M A Atkinson; N K Maclaren
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

Review 4.  Epileptic encephalopathy.

Authors:  O Dulac
Journal:  Epilepsia       Date:  2001       Impact factor: 5.864

5.  Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.

Authors:  J Peltola; P Kulmala; J Isojärvi; A Saiz; K Latvala; J Palmio; K Savola; M Knip; T Keränen; F Graus
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

6.  Ketotic hyperglycemia and epilepsia partialis continua.

Authors:  F Placidi; R Floris; A Bozzao; A Romigi; M E Baviera; M Tombini; F Izzi; F Sperli; M G Marciani
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

7.  Type 1 diabetes mellitus and drug-resistant epilepsy: presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid.

Authors:  Takanobu Yoshimoto; Masaru Doi; Nozomi Fukai; Hajime Izumiyama; Takehiko Wago; Isao Minami; Isao Uchimura; Yukio Hirata
Journal:  Intern Med       Date:  2005-11       Impact factor: 1.271

8.  Epilepsia partialis continua--a clinical and electroencephalography study.

Authors:  J D Pandian; S V Thomas; B Santoshkumar; K Radhakrishnan; P S Sarma; S Joseph; C Kesavadas
Journal:  Seizure       Date:  2002-10       Impact factor: 3.184

9.  Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus.

Authors:  Ines C Kanter; Hagen B Huttner; Dimitre Staykov; Teresa Biermann; Tobias Struffert; Frank Kerling; Max-Josef Hilz; Peter D Schellinger; Stefan Schwab; Jürgen Bardutzky
Journal:  Epilepsia       Date:  2007-12-28       Impact factor: 5.864

10.  Non-ketotic hyperglycaemia presenting as epilepsia partialis continua.

Authors:  Ozlem Cokar; Betül Aydin; Feriha Ozer
Journal:  Seizure       Date:  2004-06       Impact factor: 3.184

View more
  1 in total

Review 1.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.